Acadia Healthcare Company, Inc. (ACHC) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed outlook. While there are positive elements such as planned bed additions and expected free cash flow in 2026, there are also negatives like reduced EBITDA guidance and persistent Medicaid volume softness. The Q&A indicates some concerns about operational challenges and regulatory impacts, but no major red flags. The lack of new partnerships or strong financial results further tempers expectations, leading to a neutral sentiment.
Key Financial Performance
Revenue (Q4 2025) $821.5 million, representing a 6.1% increase year-over-year. The increase was driven by improved volume.
Adjusted EBITDA (Q4 2025) $99.8 million. This includes a $52.7 million adjustment to the company's reserve for professional and general liability.
Revenue (Full Year 2025) $3.31 billion, an increase of 5% year-over-year. This was slightly above the upper end of the guidance range, reflecting improved volume.
Adjusted EBITDA (Full Year 2025) $608.9 million, near the upper end of the guidance range. This reflects operational improvements.
Same-Facility Revenue Growth (Q4 2025) 4.4% year-over-year, driven by a 1.3% increase in revenue per patient day and a 3.1% increase in patient days.
Start-Up Losses (Q4 2025) $12.8 million, compared to $11.2 million in Q4 2024. The increase is due to newly opened facilities.
Net Operating Costs (Q4 2025) $3.6 million associated with closed facilities.
Capital Expenditures (Q4 2025) $93 million.
Capital Expenditures (Full Year 2025) $572 million, nearly $50 million favorable to prior guidance.
Costs Related to Government Investigation (Q4 2025) $12 million, down 69% sequentially.
Cash and Cash Equivalents (As of December 31, 2025) $133.2 million.
Available Credit (As of December 31, 2025) Approximately $595 million available under the $1 billion revolving credit facility.
Net Leverage Ratio (As of December 31, 2025) Approximately 4x adjusted EBITDA.
Beds Added (Q4 2025) 181 beds, including 144 beds from a new joint venture facility in North Carolina.
Beds Added (Full Year 2025) 1,089 beds, exceeding the high end of the guidance range. This includes 778 beds from opening 6 new facilities.
Facilities Closed (2025) 5 facilities, including 4 specialty facilities and 1 acute care hospital, totaling 382 beds.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New hospital openings: Acadia is focused on 2026 openings and has adjusted its planning process to ensure successful execution.
Joint ventures: In 2025, Acadia opened new joint venture facilities with Henry Ford in Michigan, Geisinger in Pennsylvania, Ascension in Texas, ECU Health in North Carolina, and Fairview in Minnesota.
De novo facilities: Acadia opened 15 new de novo facilities in its CTC line of business in 2025, expanding into underserved markets.
Bed expansion: Acadia added more than 2,500 beds over the past 3 years and plans to add 400-600 beds in 2026.
New markets: Acadia expanded its footprint through joint ventures and de novo facilities, targeting underserved markets.
Operational focus: Acadia is shifting focus from expansion to operational excellence and execution to unlock EBITDA and free cash flow potential.
Quality and safety: Acadia is expanding outcomes tracking across more programs in 2026 and leveraging technology to identify safety risks earlier.
Cost management: Costs related to managing government investigations decreased by 69% sequentially in Q4 2025.
Leadership transition: Debbie Osteen returned as CEO, focusing on stability, execution, and operational discipline.
Regulatory adjustments: Acadia is consolidating its footprint in New York due to Medicaid policy changes, closing two leased specialty facilities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Leadership Transition: The company is undergoing a leadership transition, which may pose risks to stability and execution during this period of change.
Operational Misses: Operational misses have been identified, often due to missed details rather than flawed strategy, which could impact performance.
Facility Ramp-Up Challenges: Some newer facilities have not ramped up as quickly as expected, requiring individual evaluations and adjustments to planning processes.
Regulatory Matters: The company is cooperating with government investigations, which could pose financial and reputational risks.
Start-Up Losses: Start-up losses for newly opened facilities were $12.8 million in Q4 2025 and are expected to continue in 2026, impacting financial performance.
Closed Facilities: The closure of five facilities in 2025, including four specialty facilities and one acute care hospital, resulted in operational and financial adjustments.
New York Medicaid Policy Change: The State of New York's decision to disallow Medicaid patients from receiving care in out-of-state facilities is expected to have a $25 million to $30 million annual EBITDA impact.
Supplemental Payment Revenue Decline: A decrease in Medicaid supplemental payment revenue, including a nonrecurring $34 million benefit in 2025, will impact 2026 financials.
Severe Weather Impact: Severe weather is expected to have a $3.7 million impact in Q1 2026.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections for 2026: Full year 2026 revenue is expected to be between $3.37 billion and $3.45 billion.
Adjusted EBITDA for 2026: Expected to range between $575 million and $610 million.
Adjusted EPS for 2026: Projected to be between $1.30 and $1.55.
Same-Facility Volume Growth: Anticipated to grow between 0% and 1% for 2026, driven by ramping beds and offset by a 350 basis point headwind from changes in the New York Medicaid program.
Same-Facility Revenue Per Patient Day: Expected to increase by 2% to 3% in 2026.
Start-Up Losses: Projected to range between $47 million and $53 million in 2026, with approximately 60% occurring in the first half of the year.
Capital Expenditures (CapEx): Expected to decline to a range of $255 million to $280 million in 2026.
Bed Additions: Between 400 and 600 new beds are expected to be added in 2026, primarily through new facilities nearing completion.
Supplemental Payment Revenue: 2026 guidance includes a decrease in Medicaid supplemental payment revenue, with a nonrecurring $34 million benefit from 2025 not expected to recur.
New York Medicaid Program Impact: Estimated $25 million to $30 million annual EBITDA impact due to changes in the program, with efforts to consolidate the footprint and backfill occupancy.
Free Cash Flow: Expected to be positive in 2026.
First Quarter 2026 Revenue: Projected to fall between $820 million and $830 million.
First Quarter 2026 Adjusted EBITDA: Expected to range between $130 million and $137 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the status of the value creation review initiated last year?
A:The value creation review is not on hold. The company is focused on immediate progress for 2026 and addressing issues from 2025. They are also aligning service lines to create shareholder value, with a focus on both short-term and long-term value.
Q:Is there any reason to think the growth algorithm for the industry has changed?
A:No, the demand remains strong, and there is no indication of changes to the growth algorithm. The company expects to return to normal growth as stability improves and bed closures decrease.
Q:What is the timeline for realizing the $200 million incremental EBITDA from development activity?
A:The timeline is within 5 years, but the company has not committed to a specific timeframe (e.g., 3 or 4 years). The focus is on increasing occupancy and eliminating barriers to realize investments quickly.
Q:What are the obvious areas for improvement in the company?
A:The company is focusing on removing internal barriers to problem-solving, improving operational discipline, and ensuring the right people are in place. Specific details were not provided.
Q:How does the company plan to address managed Medicaid pressures on average length of stay?
A:The company has stable length of stay metrics and addresses challenges individually. They advocate for patients and work with payers to ensure patients are in the right setting. The New York Medicaid policy has impacted length of stay, but overall, no significant changes are anticipated.
Q:What is the company's approach to bed closures and net bed growth?
A:The company does not anticipate further accelerated bed closures unless there is no clear path to viability. The focus is on operating and improving the existing portfolio. Two leased facilities in Pennsylvania were closed due to efficiency and lease expiration.
Q:How does the company plan to rebuild trust with referral sources?
A:The company maintains good referral relationships and focuses on delivering high-quality care. They aim to build trust through consistent performance, outcome data, and addressing referral sources' needs.
Q:What are the company's priorities for the next 90 to 180 days?
A:The priorities include improving volume, focusing on same-store growth, ramping up new beds, ensuring the right team is in place, and improving operational discipline using data for problem-solving and decision-making.
Q:What is the long-term plan for capital expenditures (CapEx)?
A:CapEx is expected to significantly reduce in 2026, leading to free cash flow growth. The focus will be on bed expansions at existing facilities, which are considered the best use of capital. M&A is not a short-term focus unless a great opportunity arises.
Q:What is the company's view on medical malpractice (med mal) expenses?
A:The company expects med mal expenses to stabilize, with no significant changes in claims trends. Investments in training and quality care are expected to reduce future incidents.
Q:What caused the increase in DSO (days sales outstanding)?
A:The increase was due to slower payments from two states with program finalizations and supplemental payments. Denial rates were in line with expectations, and cash collection is expected to improve in 2026.
Q:Are there risks of other states limiting out-of-state care similar to New York?
A:The company views New York as an outlier and does not anticipate similar risks in other states. Efforts are being made to diversify payer mix and find new referral sources.
Q:What is contributing to the 6% to 7% core EBITDA growth?
A:The growth is driven by ramping facilities opened between 2023 and 2025, which are gaining occupancy and leveraging fixed costs.
Q:How is the company preparing for California's new staffing requirements?
A:The company expects a $4 million EBITDA impact in 2026 due to higher staffing costs. They are working with the California Hospital Association to advocate for funding offsets for the new regulatory requirements.
Q:What are the challenges in ramping up new facilities?
A:Challenges include delays in licensure, billing tie-ins, and construction. The company plans to address these issues earlier in the process to improve ramping timelines.
Q:What is the company's approach to operational layers and leadership structure?
A:The company is reviewing corporate and field leadership structures to ensure they support field operations. Changes are being made to rightsize the organization and support growth.
Q:What drove the better-than-expected volume performance in Q4?
A:The better performance was broad-based, with strength in both acute and specialty services.
Q:What is the company's plan for cash flow and leverage?
A:The company expects to be cash flow positive in 2026, with leverage remaining in a reasonable range despite potential legal settlements. Free cash flow and EBITDA growth are expected in subsequent years.
Q:What is the impact of underperforming de novos on EBITDA?
A:Start-up losses are expected to improve modestly in 2026 compared to 2025, with further improvements in 2027 as facilities ramp up.
Q:What is the volume growth expectation for 2026?
A:Core growth is expected to be 1% to 2%, with an additional 1% to 2% benefit from ramping facilities. The New York Medicaid impact is a 3.5% drag, which is not expected to repeat in future years.
Q:What is the company's focus regarding service lines?
A:The focus is on improving performance across all service lines, particularly acute care. The CTC service line is considered strategic due to its low capital and labor intensity and strong demand.
Q:Are there staffing issues impacting new bed ramp-up?
A:Staffing is not a significant barrier. The main challenges are regulatory approvals and billing tie-ins. The company is leveraging strong partnerships to address these issues.
Q:How is the company using quality dashboards?
A:The dashboards provide immediate visibility into performance metrics, which are used for problem-solving and decision-making. Outcome data is also used to demonstrate value to payers and referral sources.
Q:What is the referral channel mix, and how is it evolving?
A:The referral mix has not significantly changed and includes emergency rooms, professional relationships, and state-specific sources. The company focuses on maintaining and strengthening these relationships.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the pace of realizing the $200 million incremental EBITDA, the exact changes being made to operational layers and leadership structure, and the specific areas of improvement being targeted in the divisional or reporting structure. Additionally, they did not provide clarity on the timing of shifts in payer mix for Pennsylvania facilities or the exact impact of underperforming de novos on EBITDA in 2026.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Acadia opportunity
CTC line
Debbie
Health
New York
North Carolina
Senior Vice
Vice President
York Medicaid
accountability
bed opening
benefit
detail
discipline
facility change
field fundamental
footprint market
foundation
health service
loss result
mission
outlook assumption
patient care
payment program
priority
provider
risk
safety
specialty facility
survey
team field
transition
value
venture facility
work
ACHC Transcript
Acadia Healthcare Company, Inc. (ACHC) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Neutral3-2
Loblaw Companies Limited (L:CA) Q4 2025 Earnings Call Transcript
Unknown2-25
The earnings call presents a mixed outlook. While there are positive developments such as new partnerships and expected free cash flow by 2026, there are also concerns about reduced EBITDA guidance, facility closures, and ongoing cost pressures. The Q&A section reveals management's reluctance to provide specifics on certain costs and timelines, adding uncertainty. The overall sentiment is balanced between positive strategic moves and negative financial adjustments, leading to a neutral stock price prediction.
Acadia Healthcare Company, Inc. (ACHC) Q4 2025 Earnings Call Transcript
Unknown2-25
The earnings call summary presents a mixed outlook. While there are positive elements such as planned bed additions and expected free cash flow in 2026, there are also negatives like reduced EBITDA guidance and persistent Medicaid volume softness. The Q&A indicates some concerns about operational challenges and regulatory impacts, but no major red flags. The lack of new partnerships or strong financial results further tempers expectations, leading to a neutral sentiment.
Acadia Healthcare Company, Inc. (ACHC) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-11
ACHC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
